Relationship of left ventricular diastolic function to obesity and overweight in a Japanese population with preserved left ventricular ejection fraction

Circulation Journal

Volumn 80, Issue 9, 2016, Pages 1951-1956

  Lee, Seitetsu L ^a   Daimon, Masao ^a   Di Tullio, Marco R ^b   Homma, Shunichi ^b   Nakao, Tomoko ^a   Kawata, Takayuki ^a   Kimura, Koichi ^a   Shinozaki, Tomohiro ^a   Hirokawa, Megumi ^a   Kato, Tomoko S ^a,c   Mizuno, Yoshiko ^a   Watanabe, Masafumi ^a   Yatomi, Yutaka ^a   Yamazaki, Tsutomu ^a   Komuro, Issei ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diastolic dysfunction; Echocardiography; Japanese; Obesity; Risk factors

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; E/A RATIO; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART RATE; HUMAN; HYPERTENSION; JAPANESE (PEOPLE); LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PEAK EARLY DIASTOLIC VELOCITY; QUESTIONNAIRE; AGED; BIOLOGICAL MODEL; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DIAGNOSTIC IMAGING; HEART FAILURE, DIASTOLIC; HEART LEFT VENTRICLE FUNCTION; JAPAN; PATHOPHYSIOLOGY;

AGED; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE, DIASTOLIC; HUMANS; JAPAN; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; OBESITY; VENTRICULAR FUNCTION, LEFT;

EID: 84983335542     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-16-0381     Document Type: Article

References (39)

1. World Health Organization. Obesity and overweight. Fact sheet no. 311. WHO, 2015. http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed April 8, 2016.)
2. Yatsuya H, Li Y, Hilawe EH, Ota A, Wang C, Chiang C, et al. Global trend in overweight and obesity and its association with cardiovascular disease incidence. Circ J 2014; 78: 2807–2818.
3. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305–313.
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: Heart disease and stroke statistics–2014 update: A report from the American Heart Association. Circulation 2014; 129: 399–410.
5. Levy WC, Anand IS. Heart failure risk prediction models: What have we learned? JACC Heart Fail 2014; 2: 437–439.
6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147–e239, doi:10.1016/j.jacc.2013.05.019.
7. Hogg K, Swedberg K, Mcmurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004; 43: 317–327.
8. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50: 768–777.
9. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251–259.
10. Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol 2006; 47: 500–506.
11. Mcmurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–1847.
12. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, et al. Effect of obesity and overweight on left ventricular diastolic function: A community-based study in an elderly cohort. J Am Coll Cardiol 2011; 57: 1368–1374.
13. Shai I, Jiang R, Manson JE, Stampfer MJ, Willett WC, Colditz GA, et al. Ethnicity, obesity, and risk of type 2 diabetes in women: A 20-year follow-up study. Diabetes Care 2006; 29: 1585–1590.
14. Hinderliter AL, Light KC, Willis PW 4th. Racial differences in left ventricular structure in healthy young adults. Am J Cardiol 1992; 69: 1196–1199.
15. Schieken RM, Schwartz PF, Goble MM. Tracking of left ventricular mass in children: Race and sex comparisons: The MCV Twin Study–Medical College of Virginia. Circulation 1998; 97: 1901–1906.
16. Harshfield GA, Koelsch DW, Pulliam DA, Alpert BS, Richey PA, Becker JA. Racial differences in the age-related increase in left ventricular mass in youths. Hypertension 1994; 24: 747–751.
17. Nakatani S, Akaishi M, Asanuma T, Hashimoto S, Izumi C, Iwanaga S, et al. Guidelines from the Japanese Society of Echocardiography: Guidance for the management and maintenance of echocardiography equipment. J Echocardiogr 2015; 13: 1–5.
18. Who Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157–163.
19. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1–39.e14, doi:10. 1016/j.echo.2014.10.003.
20. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57: 450–458.
21. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22: 107–133.
22. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta Stone. J Am Coll Cardiol 1997; 30: 8–18.
23. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, et al. Effect of diabetes and hypertension on left ventricular diastolic function in a high-risk population without evidence of heart disease. Eur J Heart Fail 2010; 12: 454–461.
24. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–1566.
25. Kosmala W, O’moore-Sullivan TM, Plaksej R, Kuliczkowska-Plaksej J, Przewlocka-Kosmala M, Marwick TH. Subclinical impairment of left ventricular function in young obese women: Contributions of polycystic ovary disease and insulin resistance. J Clin Endocrinol Metab 2008; 93: 3748–3754.
26. Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B, et al. Alterations in left ventricular structure and function in young healthy obese women: Assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 2004; 43: 1399–1404.
27. Pascual M, Pascual DA, Soria F, Vicente T, Hernandez AM, Tebar FJ, et al. Effects of isolated obesity on systolic and diastolic left ventricular function. Heart 2003; 89: 1152–1156.
28. Wong CY, O’moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004; 110: 3081–3087.
29. 2). Am J Cardiol 2004; 94: 1087–1090.
30. Dote K, Miyasaka Y, Tsujimoto S, Motohiro M, Maeba H, Suwa Y, et al. Obesity as an independent risk for left ventricular diastolic dysfunction in 692 Japanese patients. Obes Res Clin Pract 2012; 6: e175–e262, doi:10.1016/j.orcp.2012.01.001.
31. Wada H, Shinjo D, Kameda S, Ono K, Satoh N, Morimoto T, et al. Transmitral E/A ratio decreases in association with abdominal fat accumulation in patients with impaired glucose tolerance or mild diabetes without left ventricular hypertrophy. Heart Vessels 2010; 25: 45–50.
32. Suh S, Lee MK. Metabolic syndrome and cardiovascular diseases in Korea. J Atheroscler Thromb 2014; 21(Suppl 1): S31–S35.
33. Enomoto M, Ishizu T, Seo Y, Yamamoto M, Suzuki H, Shimano H, et al. Subendocardial systolic dysfunction in asymptomatic normotensive diabetic patients. Circ J 2015; 79: 1749–1755.
34. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: A noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527–1533.
35. Kosmala W, O’moore-Sullivan T, Plaksej R, Przewlocka-Kosmala M, Marwick TH. Improvement of left ventricular function by lifestyle intervention in obesity: Contributions of weight loss and reduced insulin resistance. Diabetologia 2009; 52: 2306–2316.
36. Meyer TE, Kovacs SJ, Ehsani AA, Klein S, Holloszy JO, Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol 2006; 47: 398–402.
37. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 2016; 315: 36–46.
38. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104: 1615–1621.
39. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110: 1456–1462.